5-Hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: Potential role in chemosensitization

Molecular Cancer Research

Volumn 8, Issue 1, 2010, Pages 107-118

  Sandur, Santosh K ^a   Pandey, Manoj K ^a   Sung, Bokyung ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; CYCLIN D1; JANUS KINASE 1; JANUS KINASE 2; MENADIONE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLUMBAGIN; PROTEIN BCL XL; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT3 PROTEIN; THALIDOMIDE; VANADIC ACID; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL POPULATION; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

CELL LINE, TUMOR; CELL NUCLEUS; DNA; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; HUMANS; MODELS, BIOLOGICAL; NAPHTHOQUINONES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VITAMIN K 3;

PLUMBAGO ZEYLANICA;

EID: 75149117841     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0257     Document Type: Article

References (51)

1. Tilak JC, Adhikari S, Devasagayam TP. Antioxidant properties of Plumbago zeylanica, an Indian medicinal plant and its active ingredient, plumbagin. Redox Rep 2004;9:219-27.
2. Binder RG, Benson ME, Flath RA. Eight 1,4-Naphthoquinones from Juglone. Phytochemistry 1989;28:2799-801.
3. Hedin PA, Collum DH, Langhans VE, Graves CH. Distribution of Juglone and related compounds in pecan and their effects on Fusicladium effusum. J Agric Food Chem 1980;28:340-2.
4. 2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 2006;5:3209-21.
5. Hsu YL, Cho CY, Kuo PL, Huang YT, Lin CC. Plumbagin (5-hydroxy-2-methyl- 1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther 2006;318:484-94.
6. Gomathinayagam R, Sowmyalakshmi S, Mardhatillah F, Kumar R, Akbarsha MA, Damodaran C. Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res 2008;28:785-92.
7. Thasni KA, Rakesh S, Rojini G, Ratheeshkumar T, Srinivas G, Priya S. Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents. Ann Oncol 2008;19:696-705.
8. Zhao YL, Lu DP. Effects of plumbagin on the human acute promyelocytic leukemia cells in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14:208-11.
9. Wang CC, Chiang YM, Sung SC, Hsu YL, Chang JK, Kuo PL. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett 2008;259:82-98.
10. Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res 2008;68:9024-32.
11. Powolny AA, Singh SV. Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm Res 2008; 25:2171-80.
12. Jaiswal AS, Bloom LB, Narayan S. Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclindependent kinase inhibitor p21Waf-1/Cip-1. Oncogene 2002;21: 5912-22.
13. Kawiak A, Piosik J, Stasilojc G, et al. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II. Toxicol Appl Pharmacol 2007;223:267-76.
14. Sandur SK, Ichikawa H, Sethi G, Ahn KS, Aggarwal BB. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-κB activation and NF-κB-regulated gene products through modulation of p65 and IκBα kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 2006;281:17023-33.
15. Rossary A, Arab K, Steghens JP. Polyunsaturated fatty acids modulate NOX 4 anion superoxide production in human fibroblasts. Biochem J 2007;406:77-83.
16. Shukla S, Wu CP, Nandigama K, Ambudkar SV. The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther 2007;6:3279-86.
17. Singh UV, Udupa N. Reduced toxicity and enhanced antitumor efficacy of βcyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. Indian J Physiol Pharmacol 1997;41: 171-5.
18. Tiwari SB, Pai RM, Udupa N. Temperature sensitive liposomes of plumbagin: characterization and in vivo evaluation in mice bearing melanoma B16F1. J Drug Target 2002;10:585-91.
19. Devi PU, Rao BS, Solomon FE. Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse Ehrlich ascites carcinoma in vivo. Indian J Exp Biol 1998;36:891-5.
20. Abdul KM, Ramchender RP. Modulatory effect of plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) on macrophage functions in BALB/c mice. I. Potentiation of macrophage bactericidal activity. Immunopharmacology 1995;30:231-6.
21. Jackson JK, Higo T, Hunter WL, Burt HM. Topoisomerase inhibitors as anti-arthritic agents. Inflamm Res 2008;57:126-34.
22. Nair S, Nair RR, Srinivas P, Srinivas G, Pillai MR. Radiosensitizing effects of plumbagin in cervical cancer cells is through modulation of apoptotic pathway. Mol Carcinog 2008;47:22-33.
23. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18:254-67.
24. Aggarwal BB, Sethi G, Ahn KS, et al. Targeting signal-transducerand- activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006; 1091:151-69.
25. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 2009;1171:59-76.
26. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81-3.
27. Brierley MM, Fish EN. Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 2005;25:733-44.
28. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332:83-5.
29. Schreiner SJ, Schiavone AP, Smithgall TE. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 2002;277:45680-7.
30. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996;84:331-4.
31. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 2006;108:2796-803.
32. Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003;306:1-12.
33. Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 2002;62:6390-4.
34. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991;65:701-13.
35. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
36. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006;20:1341-52.
37. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003;171:3863-71.
38. Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol 2008;19:329-40.
39. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
40. Tenev T, Bohmer SA, Kaufmann R, et al. Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. Eur J Cell Biol 2000;79:261-71.
41. Woetmann A, Nielsen M, Christensen ST, et al. Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci U S A 1999;96:10620-5.
42. Kim H, Baumann H. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol 1999;19:5326-38.
43. Yu Z, Zhang W, Kone BC. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor κB. Biochem J 2002; 367:97-105.
44. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature 2001;412:641-7.
45. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999;59:5059-63.
46. Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998;58: 256-62.
47. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997;90:1208-16.
48. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006;132:584-93.
49. Nigorikawa K, Yoshikawa K, Sasaki T, et al. A naphthoquinone derivative, shikonin, has insulin-like actions by inhibiting both phosphatase and tensin homolog deleted on chromosome 10 and tyrosine phosphatases. Mol Pharmacol 2006;70:1143-9.
50. Markovits J, Wang Z, Carr BI, et al. Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells. Life Sci 2003;72:2769-84.
51. Hsieh YJ, Lin LC, Tsai TH. Measurement and pharmacokinetic study of plumbagin in a conscious freely moving rat using liquid chromatography/ tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006;844:1-5.